Current Climate & Challenges:

Cardiovascular disease (CVD) remains England’s leading cause of death and a top NHS priority. Over 425,000 people are waiting for routine heart care, a 4% year-on-year rise, with 40% waiting more than 18 weeks. These delays increase harm and drive excess mortality (over 400 avoidable deaths annually from procedures such as TAVI, where waits average 142 days).

Pressure points include diagnostics bottlenecks, stretched imaging and echo capacity, and workflow inefficiencies slowing referral-to-treatment times. Therapeutic access and optimisation also need attention, new lipid-lowering, anti-thrombotic, and heart failure drugs can reduce events but remain underused or delayed in reaching patients.

Regional and gender disparities persist, women remain 39% less likely to receive valve replacements, and patients in deprived areas wait longer for advanced interventions.

This contributes to rising emergency demand, winter A&E crises, and the urgent need to scale innovative technologies, streamline care pathways, and accelerate both interventional and pharmaceutical therapies.

Timeliness of the Event:

The NHS 10-Year Health Plan (July 2025) prioritises cardiovascular care as an early action area. CardioVision 2026 is timed to bring together senior leaders as they implement three core system shifts:

• From hospital to community, expanding local capacity, including pharmacies as key access points for testing and medication optimisation.
• From analogue to digital, building imaging networks, remote monitoring, and data-led therapeutic decision support.
• From sickness to prevention, reinforcing early detection and risk factor control to reduce downstream demand.

Key NHS goals now driving transformation:

• Diagnostics & imaging expansion, echocardiography, advanced cardiac imaging, and point-of-care testing.
• Intervention & therapy optimisation, faster access to TAVI, PCI, and timely initiation of evidence-based pharmacological treatments.
• Workflow redesign, integrated patient pathways across primary care, pharmacy, and secondary care.
• Remote & self-monitoring, wearables, self-testing, and community follow-up to improve adherence and outcomes.

Key Subjects Covered:

• Policy & strategy alignment: Turning NHS priorities into actionable cardiovascular service models.
• Imaging & diagnostics innovation: Scaling echo, MRI, CT and point-of-care solutions, including pharmacy-based testing.
• Early & advanced treatment access: Improving referral speed and reducing waiting times for interventions and pharmaceutical therapies.
• Workflow & pathway redesign: Data-driven coordination across primary, community, pharmacy, and acute care.
• Digital & remote monitoring: Wearables, self-testing, and virtual wards to improve adherence and reduce readmissions.
• Pharmacy & medicine optimisation: Harnessing community pharmacy for detection, prescribing support, and therapy titration.
• Equity & access: Closing gender and regional gaps in diagnostics, therapy, and intervention.

Why Attend:

By attending CardioVision 2026, you will:

• Gain insight into how the NHS is accelerating diagnostics, imaging, and pharmaceutical adoption.
• Learn practical methods to optimise therapy initiation and titration alongside procedural interventions.
• Explore pharmacy-led testing and medicine optimisation models that increase reach and speed of care.
• Discover workflow and digital innovations improving efficiency and outcomes.
• Hear real-world case studies showcasing tech-enabled early detection and therapeutic intervention.
• Network with NHS leaders, cardiologists, commissioners, pharmaceutical innovators, imaging specialists, and digital health pioneers.